Academic Journal
NETest in advanced high-grade gastroenteropancreatic neuroendocrine neoplasms.
| Τίτλος: | NETest in advanced high-grade gastroenteropancreatic neuroendocrine neoplasms. |
|---|---|
| Συγγραφείς: | Sorbye H; Department of Oncology, Haukeland University Hospital and Department of Clinical Science, University of Bergen, Bergen, Norway., Hjortland GO; Department of Oncology, Oslo University Hospital, Oslo, Norway., Vestermark LW; Danish Medicines Agency, Copenhagen, Denmark., Sundlov A; Division of Oncology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden., Assmus J; Centre for Clinical Research, Haukeland University Hospital, Bergen, Norway., Couvelard A; Department of Pathology, AP-HP Bichat Hospital, Université Paris Cité, Paris, France., Perren A; Institute of Tissue Medicine and Pathology, University of Bern, Bern, Switzerland., Langer SW; Department of Oncology, Copenhagen University Hospital - Rigshospitalet and Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark. |
| Πηγή: | Journal of neuroendocrinology [J Neuroendocrinol] 2024 Nov; Vol. 36 (11), pp. e13428. Date of Electronic Publication: 2024 Jun 27. |
| Τύπος έκδοσης: | Journal Article; Observational Study |
| Γλώσσα: | English |
| Στοιχεία περιοδικού: | Publisher: Wiley & Sons Country of Publication: United States NLM ID: 8913461 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2826 (Electronic) Linking ISSN: 09538194 NLM ISO Abbreviation: J Neuroendocrinol Subsets: MEDLINE |
| Imprint Name(s): | Publication: <2010->: Malden, MA : Wiley & Sons Original Publication: Eynsham, Oxon, UK : Oxford University Press, c1989- |
| Ιατρικοί όροι (MeSH): | Pancreatic Neoplasms*/pathology , Pancreatic Neoplasms*/diagnosis , Pancreatic Neoplasms*/drug therapy , Neuroendocrine Tumors*/pathology , Neuroendocrine Tumors*/diagnosis , Intestinal Neoplasms*/pathology , Intestinal Neoplasms*/drug therapy , Intestinal Neoplasms*/mortality , Intestinal Neoplasms*/diagnosis , Stomach Neoplasms*/pathology , Stomach Neoplasms*/drug therapy , Stomach Neoplasms*/diagnosis, Biomarkers, Tumor/blood ; Humans ; Male ; Female ; Middle Aged ; Aged ; Adult ; Aged, 80 and over ; Neoplasm Grading ; Prospective Studies |
| Περίληψη: | Molecular blood biomarkers are lacking for high-grade (HG) gastroenteropancreatic (GEP) neuroendocrine neoplasms (NEN). To histologically distinguish between neuroendocrine carcinoma (NEC), neuroendocrine tumors G3 (NET G3), adenocarcinoma and MINEN is often challenging. The mRNA-based NETest has diagnostic, prognostic and predictive value in neuroendocrine tumors G1-2 but has not been studied in HG GEP-NEN. Patients with advanced HG GEP-NEN were prospectively included in an observational study. A blood sample was collected before the start of chemotherapy and pseudonymised before NETest was performed. NETest results are expressed as an activity index (NETest score) from 0 to 100. The normal score cut-off is 20. Histological sections were pseudonymised before centralized pathological re-evaluation. Samples from 60 patients were evaluable with the NETest. Main primary tumor sites were colon (14), rectum (12), pancreas (11) and esophagus (7). Re-classification: 30 NEC, 12 NET G3, 3 HG-NEN ambiguous morphology, 8 MiNEN, 3 adenocarcinomas with neuroendocrine differentiation (ADNE), 3 adenocarcinomas and 1 NET G2. Elevated NETest (>20) was seen in 38/45 (84%) HG GEP-NEN, all 17 large-cell NEC (100%), 11/13 (85%) small-cell NEC, all ambiguous cases and 7/12 (64%) NET G3. NETest was elevated in 5/8 (63%) MiNEN, 2/3 ADNE, however not in 3 adenocarcinomas. Median survival was 10.2 months (9.6-10.8 95%CI) for evaluable HG GEP-NEN treated with palliative chemotherapy (n = 39), and survival was significantly shorter in patients with NETest >60 with an OS of only 6.5 months. This is the first study to evaluate use of the NETest in advanced HG GEP-NEN. The NETest was almost always elevated in GEP-NEC and in all large-cell NEC. The NETest was also frequently elevated in NET G3 and MiNEN, however cases were limited. Baseline NETest was not predictive for benefit of chemotherapy, however a NETest >60 was prognostic with a shorter survival for patients receiving chemotherapy. (© 2024 The Author(s). Journal of Neuroendocrinology published by John Wiley & Sons Ltd on behalf of British Society for Neuroendocrinology.) |
| References: | Nagtegaal ID, Odze RD, Klimstra D, et al. The 2019 WHO classification of tumours of the digestive system. Histopathology. 2020;76(2):182‐188. Sorbye H, Welin S, Langer SW, et al. Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study. Ann Oncol. 2013;24(1):152‐160. Walter T, Tougeron D, Baudin E, et al. Poorly differentiated gastro‐entero‐pancreatic neuroendocrine carcinomas: are they really heterogeneous? Insights from the FFCD‐GTE national cohort. Eur J Cancer. 2017;79:158‐165. Sorbye H, Grande E, Pavel M, et al. European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for digestive neuroendocrine carcinoma. J Neuroendocrinol. 2023;35(3):e13249. Elvebakken H, Perren A, Scoazec JY, et al. A consensus developed morphological re‐evaluation of 196 high‐grade gastroenteropancreatic neuroendocrine neoplasms and its clinical correlations. Neuroendocrinology. 2020;111:883‐894. Zhang P, Li Z, Li J, et al. Clinicopathological features and lymph node and distant metastasis patterns in patients with gastroenteropancreatic mixed neuroendocrine‐non‐neuroendocrine neoplasm. Cancer Med. 2021;10(14):4855‐4863. van der Veen A, Seesing MFJ, Wijnhoven BPL, et al. Management of resectable esophageal and gastric (mixed adeno)neuroendocrine carcinoma: a nationwide cohort study. Eur J Surg Oncol. 2018;44(12):1955‐1962. Venizelos A, Elvebakken H, Perren A, et al. The molecular characteristics of high‐grade gastroenteropancreatic neuroendocrine neoplasms. Endocr Relat Cancer. 2021;29(1):1‐14. Sorbye H, Baudin E, Borbath I, et al. Unmet needs in high‐grade Gastroenteropancreatic neuroendocrine neoplasms (WHO G3). Neuroendocrinology. 2019;108(1):54‐62. Donadio MD, Brito AB, Riechelmann RP. A systematic review of therapeutic strategies in gastroenteropancreatic grade 3 neuroendocrine tumors. Ther Adv Med Oncol. 2023;15:17588359231156218. Oberg K, Modlin IM, De Herder W, et al. Consensus on biomarkers for neuroendocrine tumour disease. Lancet Oncol. 2015;16(9):e435‐e446. Dam G, Gronbaek H, Sorbye H, et al. Prospective study of Chromogranin A as a predictor of progression in patients with pancreatic, small‐intestinal, and unknown primary neuroendocrine tumors. Neuroendocrinology. 2020;110(3–4):217‐224. Marotta V, Zatelli MC, Sciammarella C, et al. Chromogranin A as circulating marker for diagnosis and management of neuroendocrine neoplasms: more flaws than fame. Endocr Relat Cancer. 2018;25(1):R11‐R29. Miller HC, Frampton AE, Malczewska A, et al. MicroRNAs associated with small bowel neuroendocrine tumours and their metastases. Endocr Relat Cancer. 2016;23(9):711‐726. Malczewska A, Frampton AE, Mato Prado M, et al. Circulating MicroRNAs in small‐bowel neuroendocrine tumors: a potential tool for diagnosis and assessment of effectiveness of surgical resection. Ann Surg. 2021;274(1):e1‐e9. Gerard L, Garcia J, Gauthier A, et al. ctDNA in neuroendocrine carcinoma of gastroenteropancreatic origin or of unknown primary: the CIRCAN‐NEC pilot study. Neuroendocrinology. 2020;111:951‐964. Knappskog S, Grob T, Venizelos A, et al. Mutation Spectrum in liquid versus solid biopsies from patients with advanced gastroenteropancreatic neuroendocrine carcinoma. JCO Precis Oncol. 2023;7:e2200336. Marien L, Islam O, Chhajlani S, et al. The quest for circulating biomarkers in neuroendocrine neoplasms: a clinical perspective. Curr Treat Options Oncol. 2023;24(12):1833‐1851. Kidd M, Drozdov I, Modlin I. Blood and tissue neuroendocrine tumor gene cluster analysis correlate, define hallmarks and predict disease status. Endocr Relat Cancer. 2015;22(4):561‐575. Oberg K, Califano A, Strosberg JR, et al. A meta‐analysis of the accuracy of a neuroendocrine tumor mRNA genomic biomarker (NETest) in blood. Ann Oncol. 2020;31(2):202‐212. Kidd M, Kitz A, Drozdov I, Modlin I. Neuroendocrine tumor Omic gene cluster analysis amplifies the prognostic accuracy of the NETest. Neuroendocrinology. 2021;111(5):490‐504. van Treijen MJC, van der Zee D, Heeres BC, et al. Blood molecular genomic analysis predicts the disease course of Gastroenteropancreatic neuroendocrine tumor patients: a validation study of the predictive value of the NETest(R). Neuroendocrinology. 2021;111(6):586‐598. Korse CM, Taal BG, Vincent A, et al. Choice of tumour markers in patients with neuroendocrine tumours is dependent on the histological grade. A marker study of Chromogranin A, neuron specific enolase, progastrin‐releasing peptide and cytokeratin fragments. Eur J Cancer. 2012;48(5):662‐671. Lamarca A, Walter T, Pavel M, et al. Design and validation of the GI‐NEC score to prognosticate overall survival in patients with high‐grade gastrointestinal neuroendocrine carcinomas. J Natl Cancer Inst. 2017;109(5):djw277. Pavel M, Jann H, Prasad V, Drozdov I, Modlin IM, Kidd M. NET blood transcript analysis defines the crossing of the clinical Rubicon: when stable disease becomes progressive. Neuroendocrinology. 2017;104(2):170‐182. Filosso PL, Kidd M, Roffinella M, et al. The utility of blood neuroendocrine gene transcript measurement in the diagnosis of bronchopulmonary neuroendocrine tumours and as a tool to evaluate surgical resection and disease progression. Eur J Cardiothorac Surg. 2018;53(3):631‐639. Kidd M, Drozdov IA, Matar S, et al. Utility of a ready‐to‐use PCR system for neuroendocrine tumor diagnosis. PLoS One. 2019;14(6):e0218592. Modlin IM, Kidd M, Bodei L, Drozdov I, Aslanian H. The clinical utility of a novel blood‐based multi‐transcriptome assay for the diagnosis of neuroendocrine tumors of the gastrointestinal tract. Am J Gastroenterol. 2015;110(8):1223‐1232. Al‐Toubah T, Cives M, Valone T, Blue K, Strosberg J. Sensitivity and specificity of the NETest: a validation study. Neuroendocrinology. 2021;111(6):580‐585. Malczewska A, Witkowska M, Wojcik‐Giertuga M, et al. Prospective evaluation of the NETest as a liquid biopsy for Gastroenteropancreatic and bronchopulmonary neuroendocrine tumors: an ENETS Center of Excellence Experience. Neuroendocrinology. 2021;111(4):304‐319. Filosso PL, Oberg K, Malczewska A, et al. Molecular identification of bronchopulmonary neuroendocrine tumours and neuroendocrine genotype in lung neoplasia using the NETest liquid biopsy. Eur J Cardiothorac Surg. 2020;57(6):1195‐1202. Franceschini GM, Quaini O, Mizuno K, et al. Non‐invasive detection of neuroendocrine prostate cancer through targeted cell‐free DNA methylation. Cancer Discov. 2024;14:1‐22. Wu H, Yu Z, Liu Y, et al. Genomic characterization reveals distinct mutation landscapes and therapeutic implications in neuroendocrine carcinomas of the gastrointestinal tract. Cancer Commun (Lond). 2022;42(12):1367‐1386. Bodei L, Kidd M, Modlin IM, et al. Measurement of circulating transcripts and gene cluster analysis predicts and defines therapeutic efficacy of peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors. Eur J Nucl Med Mol Imaging. 2016;43(5):839‐851. Bodei L, Kidd MS, Singh A, et al. PRRT neuroendocrine tumor response monitored using circulating transcript analysis: the NETest. Eur J Nucl Med Mol Imaging. 2020;47(4):895‐906. Bodei L, Raj N, Do RK, et al. Interim analysis of a prospective validation of 2 blood‐based genomic assessments (PPQ and NETest) to determine the clinical efficacy of (177)Lu‐DOTATATE in neuroendocrine tumors. J Nucl Med. 2023;64(4):567‐573. |
| Contributed Indexing: | Keywords: NEC; NET G3; NETest; gastroenteropancreatic; high‐grade neuroendocrine neoplasms |
| Substance Nomenclature: | 0 (Biomarkers, Tumor) |
| SCR Disease Name: | Gastro-enteropancreatic neuroendocrine tumor |
| Entry Date(s): | Date Created: 20240627 Date Completed: 20241115 Latest Revision: 20241220 |
| Update Code: | 20260130 |
| DOI: | 10.1111/jne.13428 |
| PMID: | 38937137 |
| Βάση Δεδομένων: | MEDLINE |
| ISSN: | 1365-2826 |
|---|---|
| DOI: | 10.1111/jne.13428 |